| Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical … HI Scher, S Halabi, I Tannock, M Morris, CN Sternberg, MA Carducci, ... Journal of clinical oncology 26 (7), 1148-1159, 2008 | 2479 | 2008 |
| Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group GJ Bubley, M Carducci, W Dahut, N Dawson, D Daliani, M Eisenberger, ... Journal of Clinical Oncology 17 (11), 3461-3467, 1999 | 1144 | 1999 |
| Thalidomide ME Franks, GR Macpherson, WD Figg The Lancet 363 (9423), 1802-1811, 2004 | 906 | 2004 |
| Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma RL Piekarz, R Frye, M Turner, JJ Wright, SL Allen, MH Kirschbaum, J Zain, ... Journal of clinical oncology 27 (32), 5410-5417, 2009 | 865 | 2009 |
| Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma AG Duffy, SV Ulahannan, O Makorova-Rusher, O Rahma, H Wedemeyer, ... Journal of hepatology 66 (3), 545-551, 2017 | 828 | 2017 |
| Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human … KC Conlon, E Lugli, HC Welles, SA Rosenberg, AT Fojo, JC Morris, ... Journal of clinical oncology 33 (1), 74-82, 2015 | 757 | 2015 |
| Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms V Sandor, S Bakke, RW Robey, MH Kang, MV Blagosklonny, J Bender, ... Clinical Cancer Research 8 (3), 718-728, 2002 | 679 | 2002 |
| Antibody–drug conjugates for cancer CH Chau, PS Steeg, WD Figg The Lancet 394 (10200), 793-804, 2019 | 677 | 2019 |
| Herbal remedies in the United States: potential adverse interactions with anticancer agents A Sparreboom, MC Cox, MR Acharya, WD Figg Journal of clinical oncology 22 (12), 2489-2503, 2004 | 652 | 2004 |
| Angiogenesis inhibitors: current strategies and future prospects KM Cook, WD Figg CA: a cancer journal for clinicians 60 (4), 222-243, 2010 | 642 | 2010 |
| Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol) A Sparreboom, CD Scripture, V Trieu, PJ Williams, T De, A Yang, B Beals, ... Clinical cancer research 11 (11), 4136-4143, 2005 | 610 | 2005 |
| Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas HA Fine, WD Figg, K Jaeckle, PY Wen, AP Kyritsis, JS Loeffler, VA Levin, ... Journal of Clinical Oncology 18 (4), 708-708, 2000 | 590 | 2000 |
| Selumetinib in children with inoperable plexiform neurofibromas AM Gross, PL Wolters, E Dombi, A Baldwin, P Whitcomb, MJ Fisher, ... New England Journal of Medicine 382 (15), 1430-1442, 2020 | 586 | 2020 |
| Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer E Mueller, M Smith, P Sarraf, T Kroll, A Aiyer, DS Kaufman, W Oh, ... Proceedings of the National Academy of Sciences 97 (20), 10990-10995, 2000 | 554 | 2000 |
| Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma RL Piekarz, R Frye, HM Prince, MH Kirschbaum, J Zain, SL Allen, ES Jaffe, ... Blood, The Journal of the American Society of Hematology 117 (22), 5827-5834, 2011 | 546 | 2011 |
| Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma QC Ryan, D Headlee, M Acharya, A Sparreboom, JB Trepel, J Ye, ... Journal of Clinical Oncology 23 (17), 3912-3922, 2005 | 508 | 2005 |
| Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. AM Senderowicz, D Headlee, SF Stinson, RM Lush, N Kalil, L Villalba, ... Journal of Clinical Oncology 16 (9), 2986-2999, 1998 | 496 | 1998 |
| Drug interactions in cancer therapy CD Scripture, WD Figg Nature Reviews Cancer 6 (7), 546-558, 2006 | 486 | 2006 |
| Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. A Thibault, D Samid, AC Tompkins, WD Figg, MR Cooper, RJ Hohl, ... Clinical cancer research: an official journal of the American Association …, 1996 | 481 | 1996 |
| Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer WL Dahut, JL Gulley, PM Arlen, Y Liu, KM Fedenko, SM Steinberg, ... Journal of clinical oncology 22 (13), 2532-2539, 2004 | 455 | 2004 |
William DahutNational Cancer InstituteVerified email at mail.nih.gov